Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2005
08/04/2005US20050170344 Chds as modifiers of the p53 pathway and methods of use
08/04/2005US20050170028 Polysaccharide extract from Lycium barbarum as neuroprotective agent against beta-amyloid peptide neurotoxicity
08/04/2005US20050170027 Oleic acid ester derivative; avocado extract in n-hexane solvent
08/04/2005US20050170022 Extracts of blueberries with anti-oxidant and anti-cancer properties
08/04/2005US20050170015 thiocolchicine and an antiproliferative agent selected from paclitaxel, vinblastine, etoposide, camptothecin, cisplatin, amonafide; causing alkylation damage of DNA or affects topoisomerases or tubulin; anticarcinogenic agent
08/04/2005US20050170014 Carbonyl iron pharmaceutical dosage forms for the treatment of iron-deficiency anemia
08/04/2005US20050170013 disodium EDTA; sodium lauryl sulfate; sodium citrate; zinc chloride; and hydrogen peroxide as an oxidant blocks the inflammation chemical and biochemical pathway that leads to a dermatological inflammatory tissue reaction associated with insect bites, burns, diaper rash, jock itch, and other irritants
08/04/2005US20050170007 Ude of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix
08/04/2005US20050170003 amlodipine maleate, ethylcellulose, mannitol, or corn starch as a carrier, maleic acid, phosphoric acid sorbic acid or ascorbic acid as an acid to prevent the formation of N-(2-{[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydro-2-pyridyl]methoxy}ethyl)aspartic acid
08/04/2005US20050170002 dissolving a first quantity itraconazole in the water-miscible first organic solvent to form a first solution; mixing first solution with a second solvent to precipitate itraconazle, seeding the first solution or the second solvent or pre-suspension
08/04/2005US20050170000 Particulate materials
08/04/2005US20050169999 beta -carotene was dissolved in n-isobutyl or isobutyl acetate, hot solvent phase was dispersed in a modified water starch solution, evaporation of solvent, drying the dispersion; obtained beta -carotene used as colorant, for food, beverages, nutrition fortified food and pharmaceuticals
08/04/2005US20050169997 Loading water insoluble drugs ( Nelfinavir, midazolam or indomethacin) or nicotine as water soluble drug onto ion exchange acrylic resins using water or a water miscible or water-immiscible solvent; efficient, environmentally friendly (less cosolvent); changes in release rate of drugs, taste masking
08/04/2005US20050169993 Sustained-release formulation
08/04/2005US20050169992 Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
08/04/2005US20050169991 Sustained release torsemide dosage forms
08/04/2005US20050169990 dry mixing oxycodon (opioids) with trimethylammoniumethyl methacrylate chloride, forming tablet by granulation and compression, curing the dosage form; superior to those of uncured tablets
08/04/2005US20050169989 Generally linear effervescent oral fentanyl dosage form and methods of administering
08/04/2005US20050169988 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
08/04/2005US20050169985 mini-tablets with a core of venlafaxine hydrochloride,microcrystalline cellulose and polyvinylpyrrolidone, and a coating of a water soluble polymer and a water insoluble polymer, said minitablets filled in hard gelatin capsule; once daily dosage form
08/04/2005US20050169984 Preservation stability of drugs such as the penem antibiotic faropenem or faropenem daloxate by filling the capsule with an inorganic substance such as magnesium aluminometasilicate
08/04/2005US20050169982 Topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms; seizures, obesity, neuropathic pain, affective disorders, tobacco cessation, chronic fatigue syndrome, drug addiction; highly soluble, bioavailability
08/04/2005US20050169981 Lactose monohydrate as diluent; tablets or capsules; stability is superior than either anhydrous lactose or starch as diluent
08/04/2005US20050169971 Pellet or tablet attractive to livestock masking a drug such as benazepril; animal feed substrate, intimately mixed with coated particles of a carrier material and an active ingredient casing that is coated by a masking protective layer
08/04/2005US20050169968 Conjugates comprising a biodegradable polymer and uses therefor
08/04/2005US20050169966 Growth promoting pharmaceutical implant
08/04/2005US20050169959 Medical implants and fibrosis-inducing agents
08/04/2005US20050169958 Medical implants and fibrosis-inducing agents
08/04/2005US20050169957 Blend of a biologically compatible structural component such as an acrylic ester (co)polymer, and a copolymer having a biobeneficial or bioactive moiety, such as a block copolymer of polyethylene glycol and a polyacrylate; coating medical devices such as stents
08/04/2005US20050169948 Method and compositions for treatment of acne vulgaris and acne rosacea
08/04/2005US20050169947 Cosmetics and/or skin protective agents; derived from wood materials in high concentration
08/04/2005US20050169945 Pressurized steam percolation through solid or pasty form vitamins; skin and/or hair conditioning; aging resistance
08/04/2005US20050169930 PSCA: prostate stem cell antigen and uses thereof
08/04/2005US20050169923 monoclonal antibody prevents the growth or differentiation of the B cell; secreted by the hybridoma; therapy of autoimmune diseases, sytematic lupus erythematosus, primary biliary cirrhosis, and idiopathic thrombocytopenic purpura; biodrug
08/04/2005US20050169920 Pecam-1 modulation
08/04/2005US20050169913 Administering a monoclonal antibody or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss; inhibiting gene expression of prothrombinase
08/04/2005US20050169903 preventing side effect from treating primary disorders like cancer by administering ubiquinones; prevent to generate reactive oxygen species, decrease cell of oxidative damage
08/04/2005US20050169895 Inhibiting proliferation with a matrix of alginate polymers and Strontium coated onto a medical, implantable device: a stent, a cardiac pacemaker, a catheter, a implantable prosthetic, a surgical screw, a surgical wire, a tissue bulking implant
08/04/2005US20050169894 Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of Type III and/or Type IV phosphodiesterases
08/04/2005US20050169884 Administering an hematopoietic colony stimulating factors of sargramostim; Crohn's Disease
08/04/2005US20050169883 Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
08/04/2005US20050169882 Multi-functional polymeric materials and their uses
08/04/2005US20050169881 O(chloracetyl-carbamoyl) fumagillol -470 conjugated to hydroxypropyl(meth)acrylamide-methacrylic acid copolymer results in a water soluble composition, lowers the neurotoxicity of TNP-470, avoids penetration of TNP-470 to the cerebrospinal fluid
08/04/2005US20050169870 Methods of modulating CD200
08/04/2005US20050169845 Methods for treating urinary incontinence in mammals
08/04/2005US20050166911 preparing raw material liquid so that lactulose content within powder produced following spray drying is 10 to 50% by weight, protein content is 0.2 to 9.0 parts by weight per 1 part by weight of lactulose, and chlorine content is no more than 0.08 parts by weight per 1 part by weight of protein, drying
08/04/2005DE4416840B4 Medizinische Sonde mit Mandrin Medical probe with stylet
08/04/2005DE10356164A1 Wirkstoffkombinationen aus Licochalcon A oder einem Extrakt aus Radix Clycyrrhizae inflatae, enthaltend Licochalcon A, Phenoxyethanol und gewünschtenfalls Glycerin Active compound combinations of licochalcone A or an extract from Radix Clycyrrhizae inflatae containing licochalcone A, phenoxyethanol and, if desired, glycerol
08/04/2005DE102004002557A1 Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen Use of substituted pyrimido (5,4-d) pyrimidines for the treatment of respiratory diseases
08/04/2005DE102004001187A1 Verfahren zur Herstellung von Keto-L-gulonsäuresprühgranulaten A process for preparing keto-L-gulonsäuresprühgranulaten
08/04/2005CA2595573A1 Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase
08/04/2005CA2593571A1 Methods and compositions for facilitating metabolic control
08/04/2005CA2575952A1 Post-coupling synthetic approach for polymeric antioxidants
08/04/2005CA2554716A1 Nitrosated and/or nitrosylated compounds, compositions and methods of use
08/04/2005CA2554618A1 Ribonucleic acid compound and method of liquid-phase synthesis of oligonucleic acid compound
08/04/2005CA2554617A1 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
08/04/2005CA2554616A1 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
08/04/2005CA2554588A1 Method of preparing low-crystallinity oltipraz or amorphous oltipraz
08/04/2005CA2554334A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
08/04/2005CA2554333A1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
08/04/2005CA2554332A1 Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
08/04/2005CA2554233A1 Substituted n-cyclohexyl imidazolinones having an mch-modulatory effect
08/04/2005CA2554188A1 Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
08/04/2005CA2554150A1 Tetrahydrocarboline compounds as anticancer agents
08/04/2005CA2554138A1 Aryl substituted heterocycles, method for production and use thereof as medicaments
08/04/2005CA2554047A1 Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
08/04/2005CA2553986A1 Adjuvant compositions
08/04/2005CA2553973A1 Methods of treatment of amyloidosis using aspartyl-protease inihibitors
08/04/2005CA2553969A1 Vanilloid receptor ligands and their use in treatments
08/04/2005CA2553967A1 Pharmaceutical formulations comprising metformin and a fibrate, and processes for obtaining them
08/04/2005CA2553966A1 Vanilloid receptor ligands and their use in treatments
08/04/2005CA2553923A1 Substituted heterocyclic compounds and methods of use
08/04/2005CA2553874A1 Conformationally constrained smac mimetics and the uses thereof
08/04/2005CA2553854A1 Immunomodulatory alkaloids
08/04/2005CA2553848A1 Chemical inhibitors of soluble adenylyl cyclase (sac)
08/04/2005CA2553845A1 A method of modulating pro-inflammatory and inflammatory activity mediated by c-reactive protein
08/04/2005CA2553843A1 Stress relieving composition
08/04/2005CA2553840A1 Amino alcohol derivatives and their activity as renin inhibitors
08/04/2005CA2553836A1 Amino alcohol derivatives and their use as renin inhibitors
08/04/2005CA2553831A1 Diamino alcohols and their use as renin inhibitors
08/04/2005CA2553816A1 Di-steroidal prodrugs of ethinyl estradiol
08/04/2005CA2553815A1 Di-steroidal prodrugs of estradiol
08/04/2005CA2553803A1 Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds
08/04/2005CA2553773A1 N-type calcium channel blockers
08/04/2005CA2553729A1 Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
08/04/2005CA2553690A1 Topical co-enzyme q10 formulations and methods of use
08/04/2005CA2553649A1 Compounds for the sustained reduction of body weight
08/04/2005CA2553513A1 N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
08/04/2005CA2553468A1 Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders
08/04/2005CA2553405A1 Antidiabetic oxazolidinediones and thiazolidinediones
08/04/2005CA2553266A1 Substituted quinolines and their use as mycobacterial inhibitors
08/04/2005CA2553265A1 Modulation of line-1 reverse transcriptase
08/04/2005CA2553248A1 Treatment of cancer using benzoic acid derivatives
08/04/2005CA2553242A1 2,6-disubstituted piperidines as modulators of chemokine receptor activity
08/04/2005CA2553232A1 Substituted heterocyclic compounds and methods of use
08/04/2005CA2553221A1 Folate conjugates and complexes
08/04/2005CA2553207A1 Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
08/04/2005CA2553010A1 Thiazole derivatives as a2b antagonists
08/04/2005CA2553009A1 Organic compounds
08/04/2005CA2552988A1 Mitratapide oral solution
1 ... 4592 4593 4594 4595 4596 4597 4598 4599 4600 4601 4602 4603 4604 4605 4606 4607 4608 4609 4610 4611 4612 ... 7860